These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7747525)

  • 21. MMR vaccination, measles epidemiology and sero-surveillance in the Republic of Ireland.
    Johnson H; Hillary IB; McQuoid G; Gilmer BA
    Vaccine; 1995 Apr; 13(6):533-7. PubMed ID: 7483773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population.
    Ong G; Goh KT; Ma S; Chew SK
    J Infect; 2005 Nov; 51(4):294-8. PubMed ID: 16291282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of MMR vaccine on mumps infection in England and Wales.
    Jones AG; White JM; Begg NT
    CDR (Lond Engl Rev); 1991 Aug; 1(9):R93-6. PubMed ID: 1669792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunization of healthy children with measles-mumps-rubella trivalent vaccine simultaneously given with varicella vaccine].
    Takayama N; Kidokoro M; Suzuki K; Morita M
    Kansenshogaku Zasshi; 1992 Jun; 66(6):776-80. PubMed ID: 1331262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
    Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
    Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children.
    Miller E; Goldacre M; Pugh S; Colville A; Farrington P; Flower A; Nash J; MacFarlane L; Tettmar R
    Lancet; 1993 Apr; 341(8851):979-82. PubMed ID: 8096942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project.
    Black S; Shinefield H; Ray P; Lewis E; Chen R; Glasser J; Hadler S; Hardy J; Rhodes P; Swint E; Davis R; Thompson R; Mullooly J; Marcy M; Vadheim C; Ward J; Rastogi S; Wise R
    Pediatr Infect Dis J; 1997 May; 16(5):500-3. PubMed ID: 9154545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants.
    Dunlop JM; RaiChoudhury K; Roberts JS; Bryett KA
    Public Health; 1989 Sep; 103(5):331-5. PubMed ID: 2798746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
    Bart KJ; Orenstein WA; Hinman AR
    Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mumps meningitis and measles, mumps, and rubella vaccine.
    Colville A; Pugh S
    Lancet; 1992 Sep; 340(8822):786. PubMed ID: 1356189
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.
    Amela C; Pachón I; de Ory F
    Eur J Epidemiol; 2003; 18(1):71-9. PubMed ID: 12705626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012.
    Orlíková H; Malý M; Lexová P; Šebestová H; Limberková R; Jurzykowská L; Kynčl J
    BMC Public Health; 2016 Apr; 16():293. PubMed ID: 27036176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measles, mumps, and rubella vaccines.
    Wharton M; Cochi SL; Williams WW
    Infect Dis Clin North Am; 1990 Mar; 4(1):47-73. PubMed ID: 2407778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The incidence of rubella virus infections in Switzerland after the introduction of the MMR mass vaccination programme.
    Matter L; Bally F; Germann D; Schopfer K
    Eur J Epidemiol; 1995 Jun; 11(3):305-10. PubMed ID: 7493663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Issues related to rubella, measles and epidemic parotiditis in the Russian Federation].
    Zverev VV; Iuminova NV
    Vopr Virusol; 2004; 49(3):8-11. PubMed ID: 15188648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.